Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

Core Insights - Castle Biosciences presented new data on its risk-stratification tests, DecisionDx-SCC and DecisionDx-Melanoma, at the NCCN 2025 Annual Conference, highlighting their significant prognostic capabilities in enhancing risk stratification for skin cancer patients [1][2] Group 1: DecisionDx-SCC - A study involving 1,412 high-risk squamous cell carcinoma (SCC) patients demonstrated that integrating DecisionDx-SCC with Brigham & Women's Hospital (BWH) staging significantly improves metastatic risk prediction, with a p-value of less than 0.001 [4] - The combination of DecisionDx-SCC with BWH staging resulted in nearly a two-fold decrease in metastatic risk for Class 1 (low risk) patients and over a five-fold increase in risk for Class 2B (highest risk) patients in lower-stage NCCN High-Risk categories [4][9] - DecisionDx-SCC is a 40-gene expression profile test that categorizes patients into risk classes to inform management decisions, showing independent predictive value when integrated with existing prognostic methods [9] Group 2: DecisionDx-Melanoma - New validation data for DecisionDx-Melanoma indicated its effectiveness in predicting mortality in a real-world cohort of nearly 7,000 early-stage cutaneous melanoma patients, identifying individuals at higher risk than traditional AJCC8 staging [5][7] - The test demonstrated significant independent risk-stratification capabilities, aiding in the identification of patients who may benefit from enhanced surveillance and management strategies [7][10] - DecisionDx-Melanoma has been ordered over 191,000 times for patients diagnosed with cutaneous melanoma, supporting its clinical value through extensive peer-reviewed studies [10] Group 3: Company Overview - Castle Biosciences is a diagnostics company focused on innovative tests that guide patient care, with a portfolio that includes tests for skin cancers and other conditions [11][12] - The company aims to transform disease management by prioritizing the needs of patients, clinicians, employees, and investors [11]